Emphasizing the critical role of oxidative stress in the etiology of breast cancer, numerous reports have demonstrated that reactive oxygen species (ROS) are capable of oxidizing cell constituents such as DNA, proteins, and lipids, thereby incurring oxidative damage to cell structures. 7, 8 Excessive oxidation leads to impairment of cell functions and development of morbid conditions. 9-11 ROS directly attack lipids, which leads to the peroxidation of polyunsaturated fatty acids (PUFA). Lipid hydroperoxides derived from the PUFA are prominent intermediates of peroxidative reactions. They may undergo reductive degradations, which can either diminish or enhance cytotoxic potentials, depending on the severity of stress. In addition, the lipid hydroperoxides or related intermediates trigger signal transduction pathways calling for either greater cytoprotection (upregulation of detoxifying enzymes) or deliberate termination (apoptotic death). 12 B reast cancer is a major contributor to the overall international cancer burden. 1 In India, it is the second leading malignancy in women. 2 In our institution, breast cancer is a major female malignancy, with an annual incidence rate of 20% of all cancer cases. 3 The etiology of breast cancer is multifactorial. 4,5 However, the exact cause of breast cancer is still obscure because the disease presumably represents a complex interplay of genetic susceptibility and environmental factors. 6
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Study Design. Plasma lipids (ie, total cholesterol [TC], highdensity lipoprotein [HDL], low-density lipoprotein [LDL], very-low-density lipoprotein [VLDL], and triglycerides [TG])
were analyzed from 70 controls, 30 patients with benign breast disease (BBD), 125 untreated breast cancer patients, and 93 posttreatment follow-up samples. Methods. Samples were analyzed using highly sensitive and specific spectrophotometric methods. Results. Plasma TC, LDL, VLDL, and TG were significantly lower (p = .042, p = .003, p = .024, p = .014, respectively) in patients with BBD compared with controls. Plasma TC and HDL were significantly lower (p = .026, p = .0001, respectively), and VLDL and TG were significantly higher (p = .009, p = .05) in breast cancer patients as compared with controls. Plasma VLDL and TG were significantly higher in breast cancer patients as compared with patients with BBD. The receiver-operating characteristic curve showed that plasma TC, LDL, VLDL, and TG levels could significantly discriminate (p = .001, p = .005, p = .005, p = .005, respectively) between controls and patients with BBD. Plasma levels of TC, HDL, VLDL, and TG could significantly distinguish (p = .01, p = .002, p = .001, p = .002, respectively) between controls and breast cancer patients. Plasma levels of VLDL and TG could significantly discriminate (p = .000, p = .000, respectively) between patients with BBD and breast cancer patients. Odds ratio analysis revealed that higher levels of TC and HDL were significantly associated with a reduction in breast cancer risk (p = .01 and p = .0001, respectively), whereas higher levels of VLDL and TG were significantly associated with increased breast cancer risk (p = .001 and p = .002, respectively). Plasma VLDL and TG levels were significantly lower in complete responders as compared with pretreatment levels (p = .000, p = .000, respectively), and plasma TC and LDL levels were significantly lower in nonresponders as compared with pretreatment levels (p = .015, p = .009, respectively). Conclusion. The alterations in lipid profile levels showed a significant correlation with breast cancer risk, disease status, and treatment outcome.
Various studies have suggested that increased dietary fat or cholesterol are correlated with increased risk for occurrence of breast cancer, [13] [14] [15] prostate, 16 and colonic 17, 18 tumors. Previous reports have also shown a positive correlation between low levels of total cholesterol (TC) or triglycerides (TG) and cancer morbidity. 19, 20 Thus, evaluation of alterations in lipids and lipoproteins may enlighten the role of these important molecules in the etiology of breast cancer. Furthermore, monitoring the treatment of breast cancer patients is important as invasion and metastasis is common in these patients. Various reports have also shown an association of lipids and lipoproteins with the course of anticancer treatment, suggesting their role in treatment monitoring. [21] [22] [23] Our study aimed to assess the predictive monitoring potential of plasma levels of TC, high-density lipoprotein (HDL), low-density lipoproteins (LDL), very-low-density lipoprotein (VLDL), and TG in healthy women, patients with benign breast disease (BBD), untreated breast cancer patients, and the posttreatment levels.
Materials and Methods

Subjects
One hundred twenty-five untreated female patients (mean age, 45 years) with histologically proven breast cancer were enrolled for the study between January 2003 and July 2005 from our institution; patient demographics are summarized in Table 1 . Most patients had stage II or stage III disease, with invasive ductal carcinoma the most common histological subtype. The control group included 30 patients with BBD and 70 healthy individuals. These subjects had no history of any major illness and were not suffering from diabetes mellitus, hyperlipidemia, or thyroid disease. They were not taking any medicine known to affect lipid metabolism or hormone profiles. Ethical approval and informed consent were in place for the study. Fasting blood samples were collected from the subjects by venipuncture in heparinized vaccutes. Blood samples from the breast cancer patients were drawn before initiation of anticancer therapy. Plasma was separated and stored at -80°C until analysis.
Follow-up Samples
Posttreatment fasting blood samples (n = 93) were collected from the breast cancer patients, and routine clinical, radiological, and laboratory examinations were performed during the posttreatment follow-up to evaluate the patients' clinical status. The patients with no evidence of disease at the time of follow-up sample collection were classified as complete responders (CRs), and the patients with locoregional spread of the disease, stable/progressive disease, metastasis, or recurrence were classified as nonresponders (NRs). 24
Methods
The plasma samples were precipitated for LDL and VLDL with PEG 6000 (Span Diagnostics Ltd, India). TC was measured by the CHOD-PAP method (Span Diagnostics Ltd) in plasma and HDL in the supernatant. Plasma TG levels were assessed by the GPO/Trinder method (Span Diagnostics Ltd). Plasma VLDL and LDL were calculated as: plasma VLDL = TG/5; plasma LDL = TC -VLDL -HDL.
Statistical Analysis
Data were statistically analyzed using SPSS statistical software (version 10). Values were expressed as the mean ± standard error. A Student t test was used to compare mean levels of plasma lipid profile in breast cancer patients, patients with BBD, and controls. Receiver-operating characteristic (ROC) curves were constructed to determine the discriminatory efficacy of plasma lipid profile levels between controls and patients with BBD, controls and breast cancer patients, and patients with BBD and breast cancer patients. Odds ratios (ORs) were derived by logistic regression, along with 95% confidence intervals (CIs). Pretreatment levels of the markers of the patients were paired and compared with their own posttreatment followup levels using a Student paired-sample t test. P values less than .05 were considered statistically significant. 
Results
Plasma Lipid Profile Levels in Controls, Patients With BBD and Breast Cancer Patients
Comparisons of plasma lipid profile levels between controls and patients with BBD, controls and breast cancer patients, and patients with BBD and breast cancer patients are summarized in Table 2 . Plasma TC, LDL, VLDL, and TG levels were significantly lower (P = .042, .003, .024, and .014, respectively) in patients with BBD as compared with the controls. The plasma HDL levels were comparable between controls and patients with BBD. Plasma TC and HDL levels were significantly lower (P = .026 and P = .0001, respectively), while plasma levels of VLDL and TG were significantly higher in breast cancer patients as compared with the controls (P = .009 and P = .05, respectively). Mean plasma LDL levels were lower in breast cancer patients as compared with the controls. Plasma levels of VLDL and TG were significantly higher (P = .0001 and P = .0001, respectively) in breast cancer patients as compared with the patients with BBD. Mean levels of plasma TC and HDL were lower, while LDL levels were higher in breast cancer patients as compared with the patients with BBD.
ROC Curve Analysis of Plasma Lipid Profile Parameters
Controls and BBD. The mean levels of plasma TC, LDL, VLDL, and TG could significantly discriminate (area under the curve [AUC] = 0.706, P = .001; AUC = 0.677, P = .005; AUC = 0.676, P = .005; and AUC = 0.675, P = .005, respectively) between controls and patients with BBD ( Figure 1A ).
Controls and breast cancer. The mean levels of TC, HDL, VLDL, and TG could significantly distinguish (AUC = 0.614, P = .01; AUC = 0.640, P = .002; AUC = 0.639, P = .001; and AUC = 0.636, P = .002, respectively) between controls and breast cancer patients (Figure 1Bi and 1Bii ).
BBD and breast cancer. This comparison revealed that plasma levels of VLDL and TG could significantly discriminate (AUC = 0.785, P = .000, and AUC = 0.785, P = .000, respectively) between patients with BBD and breast cancer patients (Figure 1Ci and 1Cii). Comparison of the highest with the lowest quartiles for plasma lipid profile parameters indicated that higher levels of TC and HDL with increasing quartiles were significantly associated with a reduction in risk of breast cancer (P = .01 and P = .0001, respectively), whereas higher quartiles of VLDL and TG with increasing levels were significantly associated with increased breast cancer risk (P = .001 and P = .002, respectively). OR analysis for plasma LDL levels did not reveal any significant association with breast cancer risk.
OR Risk Analysis
Plasma Lipid Profile Levels in Breast Cancer Patients With Follow-up
The paired t test was employed to compare plasma lipid profile levels in untreated breast cancer patients during their follow-up (Table 4 ). Plasma VLDL and TG levels were significantly lower in CRs as compared with pretreatment levels (P = .000 and P = .000, respectively). Mean TC and LDL levels were lower, and plasma HDL levels were comparable in CRs and pretreatment levels. Comparision of plasma lipid profile parameters between pretreatment levels and follow-up in NRs revealed that TC and LDL levels were significantly lower in NRs as compared with pretreatment levels (P = .015 and P = .009, respectively). Plasma HDL and VLDL levels were comparable, whereas plasma TG and VLDL levels were decreased in NRs as compared with pretreatment levels.
(A) Controls Vs Patients with BBD
ROC curve analysis for plasma lipid profile between controls and patients with BBD
The pattern of alterations in plasma lipid profile levels in a CR patient is shown in Figure 2A . During the course of the treatment (mastectomy followed by 6 cycles of chemotherapy), the patient responded well to the therapy. There was no evidence of disease recurrence at 15 months (F2), 18 months (F3), 21 months (F4), and 24 months (F5). Thus, the patient was a CR for the whole duration of the 24-month posttreatment follow-up. Analysis of the follow-up blood samples revealed that TC and LDL levels were above the pretreatment value and that VLDL and TG levels were below the pretreatment value throughout the follow-up duration.
An altered lipid profile pattern in an NR is shown in Figure 2B . During the course of the treatment, the patient developed pulmonary metastasis, followed by multiple fibroadenomas in the left breast (F2, 18 months) Analysis of the follow-up blood samples revealed that TC and LDL levels were below the pretreatment value and that VLDL and TG levels were above the pretreatment value throughout the follow-up duration.
Discussion
Epidemiological studies have suggested a relationship between lipids and cancer, with various studies correlating lipid abnormalities and oncogenesis. There is a high requirement of lipids for new membrane biogenesis during neoplastic processes. Cells fulfill these requirements from the circulation, by synthesis through the metabolism, or from degradation of major lipoprotein fractions such as HDL, LDL, and VLDL. Various reports have shown an association of lipids and lipoproteins with BBD as well as breast cancer patients, with contradicting results. The present investigation revealed significantly lower levels of TC, LDL, VLDL, and TG in patients with BBD as compared with the controls. Furthermore, plasma TC as well as HDL levels were significantly lower and TG and VLDL levels were higher in breast cancer patients as compared with the controls. Plasma LDL Lipid Profile in Breast Cancer / Shah et al 37 25 reported that serum lipid and apolipoprotein components of LDL were increased in women with fibrocystic disease and early-stage breast cancer. High TC and TG levels have been reported in the tissue of malignant breast tumors as compared with benign tumours. 26 A higher concentration of serum HDL was observed in breast cancer patients as compared with patients with BBD; however, no difference was observed in the serum concentration of TC, TG, and total lipids. 27 The TC and HDL values were elevated in patients with BBD as compared with breast cancer patients, but LDL and TG levels were comparable between the 2 groups. 28 Kokoglu et al 29 showed significant increases in TG and VLDL and decreases in total, HDL, and LDL cholesterol levels. In contrast, Farid et al 30 showed higher levels of cholesterol and TG in breast cancer patients. Ray and Husain 15 showed significantly elevated TC, LDL, and TG and significantly decreased HDL in breast cancer patients as compared with the controls. Fiorenza et al 20 showed significantly lower TC, LDL, and HDL in breast cancer patients than in noncancer subjects. Michalaki et al 31 showed significantly elevated levels of TG and cholesterol, whereas HDL levels were significantly decreased in patients with breast cancer as compared with controls.
The altered lipid profile status in the current study may be due to abnormal lipid metabolism associated with tumor pathogenesis and tumor host interactions, which can be supported by earlier reports. 32, 33 Malignant cells appear to metabolize lipids differently from the normal cells. Cholesterol is an essential constituent of lipoprotein fractions such as LDL, HDL, and VLDL. Seventyfive percent of TC is transported in the form of LDL. Cells sequester cholesterol from the LDL fraction of lipoproteins. LDL receptors are necessary for metabolizing circulating LDL levels, and nearly 80% of the plasma LDL is cleared by LDL receptors. 34 The low circulating cholesterol levels may be due to high LDL receptor activity. It may be possible that lower levels of LDL in the present 38 Integrative Cancer Therapies / Vol. 7, No. 1, March 2008 study may also be responsible for lower circulating cholesterol. A positive correlation between TC and LDL was also observed. Lower levels of LDL and HDL in the present study may also be due to lower antioxidant capacity owing to higher levels of ROS (data not shown), as LDL is more susceptible to oxidation by ROS, resulting in lipid peroxidation. 35 HDL is important as it counteracts the oxidative damage of LDL, thereby preventing lipid peroxidation. The mechanism for high levels of TG and low levels of HDL in breast cancer is not known. It has been suggested that lipoprotein lipase may regulate the clearance of TG from blood to tissue. 36 The activity of lipoprotein lipase in white adipose tissue decreases in cancer hosts, contributing to hypertriglyceridemia. Since precursor particles of HDL are thought to be derived from lipolysis of TG and the lipoprotein lipase activity is decreased in cancer, increased plasma TG levels may be one of the factors for a lower concentration of HDL in the present study. It is also possible that higher levels of TG may lead to decreased levels of sex hormone-binding globulin, resulting in a higher amount of free estradiol, which is likely to increase breast cancer risk. 37 The OR analysis for lipid profile indicated that higher quartiles of TC and HDL were associated with a significantly reduced risk of breast cancer, whereas higher quartiles of TG and VLDL revealed a significantly increased risk of breast cancer. Gaard et al 38 showed no association between breast cancer risk and blood lipids. ROC analysis is a more meaningful way to evaluate the discriminatory efficacy of the parameters between 2 groups in the study. It also provides sensitivity and specificity of the markers simultaneously. ROC analysis in the present study showed that TC, LDL, VLDL, and TG could significantly discriminate between controls and patients with BBD. Plasma TC, HDL, VLDL, and TG could significantly discriminate between controls and breast cancer patients, and plasma VLDL and TG could significantly discriminate between patients with BBD and breast cancer patients.
Our study also reflects the effects of cancer therapy in the alterations of plasma lipid profile levels in breast cancer patients. Comparison of plasma lipid profile levels in the untreated breast cancer patients and their followups showed that plasma levels of TG and VLDL were Lipid Profile in Breast Cancer / Shah et al 39 significantly lower in CR as compared with their pretreatment levels, while plasma levels of TC and LDL were significantly lower in NR as compared with their pretreatment values. In the present study, the plasma lipid profile in CRs showed lower plasma levels of TG and VLDL and higher TC and LDL levels throughout the follow-up duration. In NRs, VLDL and TG levels were higher and TC and LDL levels were lower than pretreatment levels throughout the follow-up duration. Variations of HDL in CRs and NRs during posttreatment follow-up duration in the current study may be due to the distribution of HDL subtractions. 31 Various studies showed altered lipid profile levels during the course of the treatment, which reversed to the normal values after completion of the treatment. [21] [22] [23] Our findings indicate that analysis of plasma lipid profile levels may predict the risk of breast cancer. Altered plasma lipid profile levels in breast cancer patients are regressed by effective treatment of the tumor, suggesting that these alterations are a secondary phenomenon of malignancy. Thus, serial monitoring of lipid profile levels could be useful as a simple, noninvasive, rapid, and dependable method for the prediction of risk, diagnosis, and for treatment outcome in breast cancer patients receiving anticancer therapy.
